Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Update of the Drug Resistance Mutations in HIV-1.
- V. Johnson, F. Brun-Vézinet, D. Richman
- Biology, MedicineTopics in HIV medicine : a publication of the…
- 1 December 2008
The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain…
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score.
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.
Evaluating the rate of within-couple HIV transmission among serodifferent heterosexual and MSM couples during periods of sex without condoms and when the HIV-positive partner had HIV-1 RNA load less than 200 copies/mL found no phylogenetically linked transmissions.
Maraviroc for previously treated patients with R5 HIV-1 infection.
Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV-1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV- 1 who were receiving OBT.
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
- M. Hirsch, H. Günthard, D. Richman
- Medicine, BiologyClinical infectious diseases : an official…
- 15 July 2008
A panel of physicians and scientists with expertise in drug-resistant HIV-1, drug management, and patient care is convened to review recently published data and presentations at scientific conferences and to provide updated recommendations on resistance testing.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised,…
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings, and resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women.
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
Results suggest that, despite suppressive HAART, active replication persists in some infected individuals and drives immune activation, and the ability of raltegravir intensification to perturb the reservoir that supports active replication has implications for therapeutic strategies aimed at achieving viral eradication.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
The data demonstrate a favorable safety profile for tenofovir DF in the treatment of adults with HIV infection, and risk factors for development of nephrotoxicity can be identified and may be useful in managing those patients at greatest risk.